Navigation Links
The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
Date:5/18/2009

ly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

Important Additional Information

The Quigley Corporation ("Quigley" or the "Company") filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on April 2, 2009 in connection with the 2009 Annual Meeting of Stockholders and began the process of mailing the definitive proxy statement and a WHITE proxy card to stockholders. The Company's stockholders are strongly advised to read Quigley's proxy statement as it contains important information. Stockholders may obtain an additional copy of Quigley's definitive proxy statement and any other documents filed by the Company with the SEC for free at the SEC's website at http://www.sec.gov. Copies of the
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
2. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
3. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
4. The Quigley Corporation Reports First Quarter 2009 Results
5. Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification
6. The Quigley Corporation Reports Fourth Quarter and 2008 Annual Results; Continues To Invest In Pharmaceutical R&D Future
7. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
8. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
9. The Quigley Corporation Names Gerard M. Gleeson to Succeed Retiring George J. Longo as Chief Financial Officer and Director
10. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
11. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 On April 2, 2015, Elle ... Achieve Kylie Jenner Lips With Disastrous Results,” ... themselves while attempting an at-home lip augmentation ... that creating an airlock around one’s mouth for several ... and achieve Kylie Jenner’s now famous pout. (see: goo.gl/dFQW2L) ...
(Date:4/21/2015)... April 21, 2015 “ ZeroWire ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... how ZeroWire is a security system and lifestyle management ... there were over 2 million burglaries in 2010. It ...
(Date:4/21/2015)... Lewisville, TX (PRWEB) April 21, 2015 ... (NYSE:ADPT) announced today it is opening its first freestanding ... located in Chandler, Arizona and will be licensed under ... of the Dignity Health and Adeptus Health joint venture. ... Chandler Regional and Mercy Gilbert Medical Centers said the ...
(Date:4/21/2015)... 2015 Wireless Analytics, LLC , ... recognized by the Boston Business Journal as the 25th ... announced at a recent event celebrating the 2015 ... fastest-growing private companies in Massachusetts. , Wireless Analytics was ... that recorded the fastest revenue growth from 2011 through ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 ... 2015” provides comparative analysis on the therapeutic ... R&D pipelines by identifying new targets and ... Complete report with TOC is available @ ... also reviews key players involved in the ...
Breaking Medicine News(10 mins):Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... Kids seem to be ignoring message that methamphetamine is ... anti-methamphetamine campaign that utilizes graphic images actually may not ... Montana Meth Project (MMP), created in 2005, featured images ... once." The perceived success of the program had resulted ...
... RALEIGH, N.C., Dec. 11 PRA International, a ... new office in,Mexico City, Mexico. With years ... market in 2005. The region,s existing base ... and infectious diseases,match favorably to PRA,s therapeutic focus. ...
... Drive China,s Psychiatric Drug Market to Reach Nearly $1 Billion ... , , WALTHAM, Mass., Dec. ... and advisory firms focusing on pharmaceutical and healthcare issues, finds ... remain. According to the new special Emerging Markets report entitled ...
... Cytometer System Twice Yearly to Support Innovative Research and Expand ... -Learn More about the Revolutionary Accuri C6 Flow ... , , ANN ARBOR, Mich., ... developing revolutionary bench-top flow cytometer systems, today announced the first ...
... Puppies , , RHINELANDER, Wis., Dec. ... Joshua Tree, California, has been an avid animal lover, trainer and ... Gene,s first dog was no exception. He would have to give ... began Gene,s life long passion for breeding and training animals. ...
... Access to Renal Function and MetLyte 8 Panels for ... UNION CITY, Calif., Dec. 11 Abaxis, Inc. (Nasdaq: ... point-of-care blood analysis systems, today announced that the U.S. ... under CLIA regulations for two additional analytes, Creatine Kinase ...
Cached Medicine News:Health News:Study Questions Value of Anti-Meth Campaign 2Health News:PRA International Expands Operations in Mexico 2Health News:China's Views on Mental Disorders Improving but Challenges Remain 2Health News:China's Views on Mental Disorders Improving but Challenges Remain 3Health News:Researcher Receives Free C6 Flow Cytometer(R) System as First Winner of Accuri Flow Cytometer(R) Creativity Awards Program 2Health News:Researcher Receives Free C6 Flow Cytometer(R) System as First Winner of Accuri Flow Cytometer(R) Creativity Awards Program 3Health News:Researcher Receives Free C6 Flow Cytometer(R) System as First Winner of Accuri Flow Cytometer(R) Creativity Awards Program 4Health News:20,000,000th Phone Order Placed at Doctors Foster & Smith Pet Supplies 2Health News:Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status 2Health News:Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status 3Health News:Abaxis Point-of-Care Test Panels Gain FDA CLIA-Waived Status 4
(Date:4/21/2015)... , April 21, 2015  Perrigo Company plc ... its Board of Directors has unanimously rejected the unsolicited ... MYL ), disclosed April 8, 2015, to acquire all ... share. Following a thorough review, advised by its financial ... Proposal substantially undervalues the Company and its future growth ...
(Date:4/21/2015)... , 21. April 2015  CorTechs Labs, ... quantitative Analyse des Hirnvolumens freut sich, eine ... Pharmaunternehmen, bekannt geben zu können. Die Unternehmen ... des Hirnvolumens zusammenarbeiten, der die Identifizierung, Messung ... Patienten mit multipler Sklerose als Ziel hat. ...
(Date:4/21/2015)... WASHINGTON , April 21, 2015 ... the National Minority Quality Forum (NMQF), today ... president of the Pharmaceutical Research and Manufacturers of ... diversity in clinical trials. On behalf of PhRMA, and ... In " campaign to build awareness, start conversations, and ...
Breaking Medicine Technology:Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 2Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 3Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 4Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 5Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 6Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 7Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 8Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 9CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 2National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 3
... 18 Misonix, Inc. (Nasdaq: MSON ), ... device technology, which worldwide is used for acute health ... Organization ("GPO") Agreement with First Choice Cooperative ("FCC"), headquartered ... Misonix will offer FCC members the opportunity to purchase ...
... Medical, Inc. (OTC Bulletin Board: AEMD ), ... infectious disease and cancer, today announced that it has ... to expand the opportunity for Aethlon to commercialize its ... centers in India.  The therapeutic focus at each center ...
Cached Medicine Technology:Misonix Announces New GPO Agreement With First Choice Cooperative 2Misonix Announces New GPO Agreement With First Choice Cooperative 3Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 2Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 3Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 4Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs 5
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established....
Used to introduce balloon, electrode, closed or non-tapered end and other catheters....
Medicine Products: